Prediction of Epidermal Growth Factor Receptors mutation in lung adenocarcinoma using clinical-morphology and CT-image features

Tyrosine kinase inhibitors (TKIs) have demonstrated favorable responses in lung adenocarcinoma patients with EGFR (Epidermal Growth Factor Receptor) mutations, leading to improved 5-year progression-free survival rates. However, identifying EGFR mutation status typically requires molecular testing through biopsy, which is invasive and may yield insufficient tissue samples. For decades, computed tomography (CT) scans have served as the primary imaging modality in the evaluation and management of